PainChek’s Scottish Trial Cuts Falls 40%, Projects £66M NHS Savings

Clinical Breakthrough in Scottish Aged Care

PainChek Limited (ASX – PCK), the developer of a pioneering AI-driven pain assessment app, has delivered compelling evidence of its clinical and economic impact through a government-funded pilot in Scotland. The independent evaluation, conducted by Edinburgh Napier University alongside the Scottish Care Inspectorate, demonstrated that the PainChek Adult App significantly improves outcomes for elderly residents in care homes.

Among the standout results were a 40% reduction in falls and a 27% decrease in dependency levels, indicating enhanced resident wellbeing and safety. Medication use also shifted positively, with analgesic prescriptions dropping by 25% and antipsychotic use falling by 33%, reflecting better pain management and fewer side effects.

Economic Impact and Healthcare Savings

Beyond clinical benefits, the pilot projected a substantial economic upside for Scotland’s healthcare system. Analysis suggests that rolling out PainChek across 60% of Scottish care homes, covering approximately 23,000 residents, could save the NHS around £66 million over five years. This translates into an impressive 10 – 1 return on investment, underscoring the app’s potential to reduce healthcare costs while improving patient care.

These findings align with Scotland’s national strategy to enhance dementia pain management, addressing both clinical efficacy and ethical considerations. Renaissance Care, the largest client involved in the trial, has already expanded PainChek usage across its 18 care homes, reporting improved resident engagement and regulatory inspection outcomes.

Integration and Global Growth Prospects

In parallel, PainChek has successfully integrated its app with InterSystems’ TrakCare electronic health record platform during a pilot at Edinburgh Royal Infirmary. This seamless integration facilitates deployment across hospitals worldwide, opening new avenues for growth beyond aged care into acute healthcare settings.

CEO Philip Daffas highlighted the dual value proposition of PainChek – "Improving patient health and reducing healthcare costs are key to securing government funding. Our Scottish pilot has demonstrated both, providing a strong foundation for UK and international expansion."

With commercial licenses already covering over 42,000 aged care beds in the UK and ongoing global partnership discussions, PainChek is well positioned to capitalize on this momentum. However, the company has yet to provide specific revenue forecasts from these initiatives, leaving investors eager for updates in upcoming quarterly reports.